Efficacy of Imatinib Mesylate for the Treatment of Locally Advanced and/or Metastatic Tenosynovial Giant Cell Tumor/ Pigmented Villonodular Synovitis
Identifieur interne : 005C98 ( Main/Exploration ); précédent : 005C97; suivant : 005C99Efficacy of Imatinib Mesylate for the Treatment of Locally Advanced and/or Metastatic Tenosynovial Giant Cell Tumor/ Pigmented Villonodular Synovitis
Auteurs : Philippe A. Cassier [France] ; Hans Gelderblom [Pays-Bas] ; Silvia Stacchiotti [Italie] ; David Thomas [Australie] ; Robert G. Maki [États-Unis] ; Judith R. Kroep [Pays-Bas] ; Winette T. Van Der Graaf [Pays-Bas] ; Antoine Italiano [France] ; Beatrice Seddon [Royaume-Uni] ; Julien Domont [France] ; Emanuelle Bompas [France] ; Andrew J. Wagner [États-Unis] ; Jean-Yves Blay [France]Source :
- Cancer [ 0008-543X ] ; 2012.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
BACKGROUND: Pigmented villonodular synovitis (PVNS) (also known as diffuse-type giant cell tumor) and tenosynovial giant cell tumors (TGCT) are rare, usually benign neoplasms that affect the synovium and tendon sheaths in young adults. These tumors are driven by the overexpression of colony stimulating factor-1 (CSF1). CSF1 is expressed by a minority of tumor cells, which, in turn attract non-neoplastic inflammatory cells that express CSF1 receptor (CSF1R) through a paracrine effect. METHODS: Imatinib mesylate (IM) blocks CSF1R, and previous case reports indicated that it also exerts antitumor activity in PVNS. The authors conducted a multi-institutional retrospective study to assess the activity of IM in patients with locally advanced/metastatic PVNS/TGCT. RESULTS: Twenty-nine patients from 12 institutions in Europe, Australia, and the United States were included. There were 13 men, the median age was 41 years, and the most common site of disease was the knee (n = 17; 59%). Two patients had metastatic disease to the lung and/or bone. Five of 27 evaluable patients had Response Evaluation in Solid Tumor (RECIST) responses (overall response rate, 19%; 1 complete response and 4 partial responses), and 20 of 27 patients (74%) had stable disease. Symptomatic improvement was noted in 16 of 22 patients (73%) who were assessable for symptoms. Despite a high rate of symptomatic improvement and a favorable safety profile, 6 patients discontinued because of toxicity, and 4 patients decided to discontinue IM for no clear medical reason. CONCLUSIONS: IM displayed interesting activity in patients with PVNS/TGCT, providing proof of concept for targeting CSF1R in this disease. The authors concluded that the benefits of alleviating morbidity in patients with localized PVNS/TGCT must be balanced against the potential toxicity of chronic drug therapy.
Affiliations:
- Australie, France, Italie, Pays-Bas, Royaume-Uni, États-Unis
- Angleterre, Aquitaine, Auvergne-Rhône-Alpes, Grand Londres, Gueldre, Hollande-Méridionale, Lombardie, Massachusetts, Nouvelle-Aquitaine, Pays de la Loire, Rhône-Alpes, État de New York
- Bordeaux, Leyde, Londres, Lyon, Milan, Nantes, Nimègue, Villeurbanne
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001518
- to stream PascalFrancis, to step Curation: 004994
- to stream PascalFrancis, to step Checkpoint: 001174
- to stream Main, to step Merge: 006009
- to stream Main, to step Curation: 005C98
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy of Imatinib Mesylate for the Treatment of Locally Advanced and/or Metastatic Tenosynovial Giant Cell Tumor/ Pigmented Villonodular Synovitis</title><author><name sortKey="Cassier, Philippe A" sort="Cassier, Philippe A" uniqKey="Cassier P" first="Philippe A." last="Cassier">Philippe A. Cassier</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Medicine, Leon Berard Center</s1><s2>Lyon</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gelderblom, Hans" sort="Gelderblom, Hans" uniqKey="Gelderblom H" first="Hans" last="Gelderblom">Hans Gelderblom</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Leiden University Medical Center</s1><s2>Leiden</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Stacchiotti, Silvia" sort="Stacchiotti, Silvia" uniqKey="Stacchiotti S" first="Silvia" last="Stacchiotti">Silvia Stacchiotti</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Cancer Medicine, National Cancer Institute</s1><s2>Milan</s2><s3>ITA</s3><sZ>3 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Thomas, David" sort="Thomas, David" uniqKey="Thomas D" first="David" last="Thomas">David Thomas</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Haematology and Medical Oncology, Peter MacCallum Cancer Center</s1><s2>East Melbourne, Victoria</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>East Melbourne, Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Maki, Robert G" sort="Maki, Robert G" uniqKey="Maki R" first="Robert G." last="Maki">Robert G. Maki</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York</s1><s2>New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kroep, Judith R" sort="Kroep, Judith R" uniqKey="Kroep J" first="Judith R." last="Kroep">Judith R. Kroep</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Leiden University Medical Center</s1><s2>Leiden</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Der Graaf, Winette T Van" sort="Der Graaf, Winette T Van" uniqKey="Der Graaf W" first="Winette T. Van" last="Der Graaf">Winette T. Van Der Graaf</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Medical Oncology, Radboud University Nijmegen Medical Center</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Italiano, Antoine" sort="Italiano, Antoine" uniqKey="Italiano A" first="Antoine" last="Italiano">Antoine Italiano</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Bergonié Institute</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Seddon, Beatrice" sort="Seddon, Beatrice" uniqKey="Seddon B" first="Beatrice" last="Seddon">Beatrice Seddon</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Oncology, University College Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Domont, Julien" sort="Domont, Julien" uniqKey="Domont J" first="Julien" last="Domont">Julien Domont</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Medicine, Gustave Roussy Institute</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Gustave Roussy Institute</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Bompas, Emanuelle" sort="Bompas, Emanuelle" uniqKey="Bompas E" first="Emanuelle" last="Bompas">Emanuelle Bompas</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Medical Oncology, Rene Gauducheau Cancer Center</s1><s2>Nantes</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Wagner, Andrew J" sort="Wagner, Andrew J" uniqKey="Wagner A" first="Andrew J." last="Wagner">Andrew J. Wagner</name><affiliation wicri:level="2"><inist:fA14 i1="11"><s1>Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Medicine, Leon Berard Center</s1><s2>Lyon</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>University of Lyon</s1><s2>Villeurbanne</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Villeurbanne</settlement><settlement type="city" wicri:auto="agglo">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0144440</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0144440 INIST</idno><idno type="RBID">Pascal:12-0144440</idno><idno type="wicri:Area/PascalFrancis/Corpus">001518</idno><idno type="wicri:Area/PascalFrancis/Curation">004994</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001174</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001174</idno><idno type="wicri:doubleKey">0008-543X:2012:Cassier P:efficacy:of:imatinib</idno><idno type="wicri:Area/Main/Merge">006009</idno><idno type="wicri:Area/Main/Curation">005C98</idno><idno type="wicri:Area/Main/Exploration">005C98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy of Imatinib Mesylate for the Treatment of Locally Advanced and/or Metastatic Tenosynovial Giant Cell Tumor/ Pigmented Villonodular Synovitis</title><author><name sortKey="Cassier, Philippe A" sort="Cassier, Philippe A" uniqKey="Cassier P" first="Philippe A." last="Cassier">Philippe A. Cassier</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Medicine, Leon Berard Center</s1><s2>Lyon</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gelderblom, Hans" sort="Gelderblom, Hans" uniqKey="Gelderblom H" first="Hans" last="Gelderblom">Hans Gelderblom</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Leiden University Medical Center</s1><s2>Leiden</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Stacchiotti, Silvia" sort="Stacchiotti, Silvia" uniqKey="Stacchiotti S" first="Silvia" last="Stacchiotti">Silvia Stacchiotti</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Cancer Medicine, National Cancer Institute</s1><s2>Milan</s2><s3>ITA</s3><sZ>3 aut.</sZ></inist:fA14><country>Italie</country><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Thomas, David" sort="Thomas, David" uniqKey="Thomas D" first="David" last="Thomas">David Thomas</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Haematology and Medical Oncology, Peter MacCallum Cancer Center</s1><s2>East Melbourne, Victoria</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>East Melbourne, Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Maki, Robert G" sort="Maki, Robert G" uniqKey="Maki R" first="Robert G." last="Maki">Robert G. Maki</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York</s1><s2>New York</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Kroep, Judith R" sort="Kroep, Judith R" uniqKey="Kroep J" first="Judith R." last="Kroep">Judith R. Kroep</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Medical Oncology, Leiden University Medical Center</s1><s2>Leiden</s2><s3>NLD</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Der Graaf, Winette T Van" sort="Der Graaf, Winette T Van" uniqKey="Der Graaf W" first="Winette T. Van" last="Der Graaf">Winette T. Van Der Graaf</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Department of Medical Oncology, Radboud University Nijmegen Medical Center</s1><s2>Nijmegen</s2><s3>NLD</s3><sZ>7 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Nimègue</settlement><region type="province" nuts="2">Gueldre</region></placeName></affiliation></author><author><name sortKey="Italiano, Antoine" sort="Italiano, Antoine" uniqKey="Italiano A" first="Antoine" last="Italiano">Antoine Italiano</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Department of Medical Oncology, Bergonié Institute</s1><s2>Bordeaux</s2><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Seddon, Beatrice" sort="Seddon, Beatrice" uniqKey="Seddon B" first="Beatrice" last="Seddon">Beatrice Seddon</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Oncology, University College Hospital</s1><s2>London</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Domont, Julien" sort="Domont, Julien" uniqKey="Domont J" first="Julien" last="Domont">Julien Domont</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Medicine, Gustave Roussy Institute</s1><s2>Villejuif</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Gustave Roussy Institute</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Bompas, Emanuelle" sort="Bompas, Emanuelle" uniqKey="Bompas E" first="Emanuelle" last="Bompas">Emanuelle Bompas</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Medical Oncology, Rene Gauducheau Cancer Center</s1><s2>Nantes</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Wagner, Andrew J" sort="Wagner, Andrew J" uniqKey="Wagner A" first="Andrew J." last="Wagner">Andrew J. Wagner</name><affiliation wicri:level="2"><inist:fA14 i1="11"><s1>Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute</s1><s2>Boston, Massachusetts</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Medicine, Leon Berard Center</s1><s2>Lyon</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="12"><s1>University of Lyon</s1><s2>Villeurbanne</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Villeurbanne</settlement><settlement type="city" wicri:auto="agglo">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Cancer</title><title level="j" type="abbreviated">Cancer</title><idno type="ISSN">0008-543X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Cancer</title><title level="j" type="abbreviated">Cancer</title><idno type="ISSN">0008-543X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term><term>Antineoplastic agent</term><term>Biological receptor</term><term>Cancerology</term><term>Chronic</term><term>Giant cell tumor</term><term>Imatinib</term><term>Locally advanced stage</term><term>Macrophage colony stimulating factor</term><term>Metastasis</term><term>Pharmacotherapy</term><term>Pigmented villonodular synovitis</term><term>Treatment</term><term>Treatment efficiency</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Imatinib</term><term>Efficacité traitement</term><term>Traitement</term><term>Métastase</term><term>Stade avancé</term><term>Pharmacothérapie</term><term>Tumeur cellule géante</term><term>Facteur stimulant colonie macrophage</term><term>Récepteur biologique</term><term>Synovite villonodulaire pigmentée</term><term>Cancérologie</term><term>Anticancéreux</term><term>Chronique</term><term>STI 571</term><term>Stade localement avancé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND: Pigmented villonodular synovitis (PVNS) (also known as diffuse-type giant cell tumor) and tenosynovial giant cell tumors (TGCT) are rare, usually benign neoplasms that affect the synovium and tendon sheaths in young adults. These tumors are driven by the overexpression of colony stimulating factor-1 (CSF1). CSF1 is expressed by a minority of tumor cells, which, in turn attract non-neoplastic inflammatory cells that express CSF1 receptor (CSF1R) through a paracrine effect. METHODS: Imatinib mesylate (IM) blocks CSF1R, and previous case reports indicated that it also exerts antitumor activity in PVNS. The authors conducted a multi-institutional retrospective study to assess the activity of IM in patients with locally advanced/metastatic PVNS/TGCT. RESULTS: Twenty-nine patients from 12 institutions in Europe, Australia, and the United States were included. There were 13 men, the median age was 41 years, and the most common site of disease was the knee (n = 17; 59%). Two patients had metastatic disease to the lung and/or bone. Five of 27 evaluable patients had Response Evaluation in Solid Tumor (RECIST) responses (overall response rate, 19%; 1 complete response and 4 partial responses), and 20 of 27 patients (74%) had stable disease. Symptomatic improvement was noted in 16 of 22 patients (73%) who were assessable for symptoms. Despite a high rate of symptomatic improvement and a favorable safety profile, 6 patients discontinued because of toxicity, and 4 patients decided to discontinue IM for no clear medical reason. CONCLUSIONS: IM displayed interesting activity in patients with PVNS/TGCT, providing proof of concept for targeting CSF1R in this disease. The authors concluded that the benefits of alleviating morbidity in patients with localized PVNS/TGCT must be balanced against the potential toxicity of chronic drug therapy.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Aquitaine</li><li>Auvergne-Rhône-Alpes</li><li>Grand Londres</li><li>Gueldre</li><li>Hollande-Méridionale</li><li>Lombardie</li><li>Massachusetts</li><li>Nouvelle-Aquitaine</li><li>Pays de la Loire</li><li>Rhône-Alpes</li><li>État de New York</li></region><settlement><li>Bordeaux</li><li>Leyde</li><li>Londres</li><li>Lyon</li><li>Milan</li><li>Nantes</li><li>Nimègue</li><li>Villeurbanne</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Cassier, Philippe A" sort="Cassier, Philippe A" uniqKey="Cassier P" first="Philippe A." last="Cassier">Philippe A. Cassier</name></region><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><name sortKey="Bompas, Emanuelle" sort="Bompas, Emanuelle" uniqKey="Bompas E" first="Emanuelle" last="Bompas">Emanuelle Bompas</name><name sortKey="Domont, Julien" sort="Domont, Julien" uniqKey="Domont J" first="Julien" last="Domont">Julien Domont</name><name sortKey="Italiano, Antoine" sort="Italiano, Antoine" uniqKey="Italiano A" first="Antoine" last="Italiano">Antoine Italiano</name></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Gelderblom, Hans" sort="Gelderblom, Hans" uniqKey="Gelderblom H" first="Hans" last="Gelderblom">Hans Gelderblom</name></region><name sortKey="Der Graaf, Winette T Van" sort="Der Graaf, Winette T Van" uniqKey="Der Graaf W" first="Winette T. Van" last="Der Graaf">Winette T. Van Der Graaf</name><name sortKey="Kroep, Judith R" sort="Kroep, Judith R" uniqKey="Kroep J" first="Judith R." last="Kroep">Judith R. Kroep</name></country><country name="Italie"><region name="Lombardie"><name sortKey="Stacchiotti, Silvia" sort="Stacchiotti, Silvia" uniqKey="Stacchiotti S" first="Silvia" last="Stacchiotti">Silvia Stacchiotti</name></region></country><country name="Australie"><noRegion><name sortKey="Thomas, David" sort="Thomas, David" uniqKey="Thomas D" first="David" last="Thomas">David Thomas</name></noRegion></country><country name="États-Unis"><region name="État de New York"><name sortKey="Maki, Robert G" sort="Maki, Robert G" uniqKey="Maki R" first="Robert G." last="Maki">Robert G. Maki</name></region><name sortKey="Wagner, Andrew J" sort="Wagner, Andrew J" uniqKey="Wagner A" first="Andrew J." last="Wagner">Andrew J. Wagner</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Seddon, Beatrice" sort="Seddon, Beatrice" uniqKey="Seddon B" first="Beatrice" last="Seddon">Beatrice Seddon</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005C98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005C98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0144440
|texte= Efficacy of Imatinib Mesylate for the Treatment of Locally Advanced and/or Metastatic Tenosynovial Giant Cell Tumor/ Pigmented Villonodular Synovitis
}}
| This area was generated with Dilib version V0.6.33. |  |